- Home
- » Tags
- » Osimertinib
Top View
- Osimertinib) Tablets, for Oral Use Cardiomyopathy: Occurred in 2.6% of Patients
- "Tagrisso, Inn-Osimertinib"
- Response to Second-Line Osimertinib in Primary EGFR P.T790M Mutation
- Title: Identification of Novel Pathways of Osimertinib Disposition And
- Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with Osimertinib Shengwu Liu1, Shuai Li2,3, Josephine Hai1, Xiaoen Wang1, Ting Chen3, Max M
- Tagrisso-Product-Monograph-En.Pdf
- Building on the Success of Osimertinib: Achieving CNS Exposure in Oncology Drug Discovery
- Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell
- Preferred Drug List 4-Tier Small Group
- The Ratio of T790M to EGFR-Activating Mutation Predicts Response of Osimertinib in 1St Or 2Nd Generation EGFR-TKI-Refractory
- Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated
- We Seek to Improve Standards of Care in Cancer Treatment
- Strategic Collaboration in Oncology Trastuzumab Deruxtecan (DS-8201)
- Osimertinib Mesylate
- An Accurate and Effective Method for Measuring Osimertinib by UPLC-TOF-MS and Its Pharmacokinetic Study in Rats
- Press Release
- Outpatient Cancer Drug Benefit Program List
- Healthcare Services Medical & Pharmacy Policy Alerts
- Daiichi Sankyo Co., Ltd
- Reimbursement Criteria for Frequently Requested Drugs
- Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation–Positive Non–Small Cell Lung Cancer Ferdinandos Skoulidis and Vassiliki A
- A Comparison Between First-, Second- and Third-Generation Epidermal
- Third-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in T790M-Positive Non-Small Cell Lung Cancer: Review on Emerged Mechanisms of Resistance
- Inhibition of Bcl-2 and Bcl-Xl Overcomes the Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer
- HER2-D16 Oncogenic Driver Mutation Confers Osimertinib Resistance in EGFR Mutation-Positive Non-Small Cell Lung Cancer
- Comparative Analysis of Drug Response and Gene Profiling Of
- New Oncology Reimbursements in Belgium
- Stage IV Non-Small Cell Lung Cancer Foreword
- Osimertinib in Advanced EGFR-T790M Mutation-Positive Non
- TAGRISSO 40 Mg Film-Coated Tablets TAGRISSO 80 Mg Film-Coated Tablets
- (EGFR) Mutation-Positive Metastatic Non-Small Cell Lung Canc
- Efficacy of Combination Treatment Using YHO-1701, an Orally Active
- HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2- Positive and HER2-Mutated Breast Cancer
- Osimertinib for Untreated EGFR Mutation-Positive Non-Small-Cell Lung Cancer (TA654)
- Precision Cancer Therapy
- ID1 Mediates Resistance to Osimertinib in EGFR T790M-Positive Non-Small Cell Lung Cancer Through Epithelial–Mesenchymal Transi
- Preclinical Comparison of Osimertinib with Other EGFR-Tkis in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of C
- Relative Risk of Peripheral Neuropathy with Ado-Trastuzumab Emtansine (T-DM1) Compared to Taxane-Based Regimens in Human Epiderm
- Generation EGFR-TKI Osimertinib in NSCLC EGFR Mutated Cell Lines
- A Promising Response to Osimertinib in a Patient with Erlotinib-Resistant
- OPALS: a New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma Or Glioblastoma Using Five Repurposed Drugs
- Brain Distribution of a Panel of EGFR Inhibitors Using Cassette-Dosing in Wild-Type and Abcb1/Abcg2 Deficient Mice
- Histopathological Features of Drug-Induced Liver Injury Secondary to Osimertinib Ivan Gonzalez Washington University School of Medicine in St
- And Second-Generation EGFR-Tkis Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
- Osimertinib (AZD9291)
- Osimertinib (Tagrisso)
- Rapid and Sensitive Quantification of Osimertinib in Human Plasma
- (Palbociclib). Ibrance Formerly Known As LEE011)In Combination Tagrisso